Supply Chain
Private equity firm Ancor Capital Partners announced Tuesday that it has acquired WellSpring Pharmaceutical Corporation, a manufacturer and marketer of specialty prescription and over-the-counter products. This is Ancor's fifteenth acquisition in the healthcare segment.
The growing drug shortage crisis is the number one supply chain concern for providers nationwide says Novation, a group purchasing organization. Yet, even in these dire circumstances, there may be a glimmer of hope.
The U.S. Department of Justice announced last week that medical device company Dfine has agreed to pay the United States $2.39 million to resolve allegations that it paid kickbacks to induce physicians to use its devices for treating spinal fractures.
Hopkins reduced 'red bag' regulated medical waste by 16 percent in part by putting appropriate trash in the correct containers.
How can you make sure that the inventory ordered for provider encounters (DME, hearing aids, CPAP machines, ER trays, etc) are being accounted for on the patient’s bill? If you are not reconciling inventory with patient accounting, you are losing potential revenue.
With U.S. drug shortages reaching record numbers, President Obama issued an executive order on Monday, directing the FDA to take steps to reduce current shortages and prevent future disruptions.
Practice Greenhealth, a nonprofit organization working to help healthcare organizations improve their environmental practices, has released the Standardized Environmental Questions for Medical Products. The questions are designed to help hospitals identify, request and procure environmentally preferable medical products.
Struggling pharmaceutical giant AstraZeneca announced plans to lay off 400 employees at its main office in Wilmington, Delaware.
The U.S. Food and Drug Administration and the Centers for Medicare & Medicaid Services have launched a parallel review pilot program that allows medical devices to be reviewed for approval by the FDA and CMS at the same time.
In light of the record drug shortages currently plaguing U.S. healthcare, Sen. Charles Schumer (D-NY) is calling for a Federal Trade Commission investigation into gray market drug resellers' exorbitant price mark-ups as possible price gouging.